Loading
JS108 is an experimental TROP-2 antibody-drug conjugate whose first clinical study was terminated.
NCT04601285 describes a humanised anti-TROP2 monoclonal antibody linked to Tub196, given intravenously every three weeks. The study enrolled 25 actual participants and was terminated after the sponsor adjusted its development plan. This study status does not establish that every future JS108 programme has been abandoned.
Humanised anti-TROP2 antibody conjugated to the microtubule inhibitor Tub196. Connects to TROP2.
1.JS108's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"JS108" OR ABSTRACT:"JS108") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about JS108, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/